



### Incidence of Melanoma

- The incidence of melanoma is increasing
- In 2018 in the U.S., an estimated 91,270 new invasive melanomas, and nearly 9,320 deaths due to melanoma
- The 5<sup>th</sup> & 6<sup>th</sup> most common cancer among U.S. men and women, respectively
- ~5% of malignant skin tumors, but 60% of skin cancer deaths

American Cancer Society. Cancer Facts and Figures 2018



---

---

---

---

---

---

---

---

### The ABCDEs of Melanoma Diagnosis

**Asymmetry**



One half of the lesion is shaped differently than the other

**Border**



The border of the lesion is irregular, blurred, or ragged

**Color**



Inconsistent pigmentation, with varying shades of brown and black

**Evolution**

History of change in the lesion

**Diameter**



>6 mm, or a progressive change in size

Photos courtesy of the American Cancer Society.

American Cancer Society

---

---

---

---


---

---

---

---

### Asymmetry on the 2 axes



---

---

---

---

---

---

---

---

UNC SCHOOL OF MEDICINE

**Ragged or Indented Borders**



6

---

---

---

---

---

---

---

---

UNC SCHOOL OF MEDICINE

**More Than 2 Colors**



7

---

---

---

---

---

---

---

---

UNC SCHOOL OF MEDICINE

**Diameter  $\geq$  6 mm**



8

---

---

---

---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---

**Melanoma**

UNC SCHOOL OF MEDICINE

12

---

---

---

---

---

---

---

---

**Types of Melanoma**

- Superficial Spreading
- Nodular
- Lentigo Maligna
- Acral Lentiginous

UNC SCHOOL OF MEDICINE

13

---

---

---

---

---

---

---

---

**Superficial Spreading Melanoma**

Most common subtype

Location – any anatomic site

UNC SCHOOL OF MEDICINE

14

---

---

---

---

---

---

---

---

### Superficial Spreading Melanoma



---

---

---

---

---

---

---

### Nodular Melanoma

Less common (about 10%)  
Location – any anatomic site



---

---

---

---

---

---

---

### Nodular Melanoma



---

---

---

---

---

---

---

### Lentigo Maligna

UNC SCHOOL OF MEDICINE

Less common (10-15%)  
Sun exposed site such as head  
or neck



18

---

---

---

---

---

---

---

### Lentigo Maligna

UNC SCHOOL OF MEDICINE



19

---

---

---

---

---

---

---

### Lentigo Maligna

UNC SCHOOL OF MEDICINE



20

---

---

---

---

---

---

---

**Lentigo Maligna Melanoma**



---

---

---

---

---

---

---

---

**Acral Lentiginous Melanoma**

Least common (5%)  
Location palms, soles



---

---

---

---

---

---

---

---

**POLL**

Which is more likely to be a melanoma based on the ABCDE criteria for melanoma?



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

### Risk Factors

**Early life ambient exposure**  
is associated with high  
rates of melanoma

**Sunburns**, especially in  
early life increase risk

---

---

---

---

---

---

---

---

**Risk Factors**



**Sun behavior associated with increased risk of melanoma**

30

---

---

---

---

---

---

---

---

**Behaviors Associated with Melanoma**



Holidays in sunnier climates



Beach activities



Sunburns

Kricker et al. Cancer Causes Control, 2006

31

---

---

---

---


---

---

---

---

**UV Listed as a Carcinogen by IARC**



International Agency for Research on Cancer (IARC) is a section of the United Nations World Health Organization (WHO) responsible for classifying agents depending on their carcinogenic (cancer causing) potential.

In 2009, the IARC categorized ultraviolet-emitting tanning devices in the highest risk class for cancer, "**Group 1: the agent (mixture) is definitely carcinogenic to humans**", along with asbestos and tobacco smoking.

32

---

---

---

---

---

---

---

---

### Artificial Tanning

UNC SCHOOL OF MEDICINE

IARC:

- The risk of melanoma goes up when you use a tanning bed at any age
- If you start using tanning beds before age 30, your risk of developing melanoma jumps by 75 percent



33

---

---

---

---

---

---

---

### Phenotypic Risk Factors

UNC SCHOOL OF MEDICINE

- Increased nevi
- Fair skin
- Red hair
- Blue Eyes
- Freckles
- Increased tendency to burn
- Decreased ability to tan

34

---

---

---

---

---

---

---

### Multiple Nevi Strongest Risk Factor

UNC SCHOOL OF MEDICINE



35

---

---

---

---

---

---

---

UNC HEALTH CARE SYSTEM

### Risk Factors: Genetics

- Family history
- Rare genetic mutations (e.g. in p16)
- Common gene polymorphisms
  - Red hair gene (*MC1R*)
  - Other pigmentation genes (*OCA2*, *HERC2*)
  - Nevus related genes (e.g. *IRF4*, *PLAQ26*)
  - Cell cycle genes e.g. (*CCND1*)
  - DNA repair genes

36

---

---

---

---

---

---

---

---

UNC HEALTH CARE SYSTEM

### POLL

Which is not a risk factor for melanoma

- A. Many freckles
- B. A family history of melanoma
- C. Brown eyes
- D. Many moles
- E. A history of sunburns

37

---

---

---

---

---

---

---

---

UNC HEALTH CARE SYSTEM

### Prevention

- Monitor and limit sun exposure especially during peak daylight hours ~10 a.m. to 3 p.m.
- Protect yourself on cloudy days, too
- Seek shade
- Wear protective clothing and sunglasses
- Liberally apply broad spectrum sunscreen, at least 15 SPF, to exposed skin

38

---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

**Prevention: Wear UV-protective clothing.**

High UPF Moderate UPF Low UPF

**Tighter weave increased protection**

**UPF = ULTRAVIOLET PROTECTION FACTORY → UPF 50**

---

---

---

---

---

---

---

---

**Sunscreen Regulation Since 2011**

- Sunscreen labels must include warnings about skin cancer
- Sunscreen labels cannot have misleading statements like ~~"Water-proof"~~ or ~~"Sunblock"~~
- FDA established water resistance testing and labelling guidelines
- New broad-spectrum testing standards
- 2014 Sunscreen Innovation Act created an improved FDA process for reviewing and approving new ingredients

UNC HEALTH CARE 43

---

---

---

---

---

---

---

---

**Sunscreen: Warnings about Skin Cancer**

**Directions** • apply generously and evenly 15 minutes before sun exposure • reapply: • after 80 minutes of swimming or sweating • immediately after towel drying • at least every 2 hours • **Sun Protection Measures:** Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including • limit time in the sun, especially from 10 a.m.–2 p.m. • wear long-sleeved shirts, pants, hats, and sunglasses • children under 6 months of age: Ask a doctor

**Other information** • protect this product from excessive

UNC HEALTH CARE 44

---

---

---

---

---

---

---

---

**Sunscreen: Water Resistant**

- No sunscreen lasts indefinitely when you're swimming or sweating so FDA bans the use of "waterproof" or "sweatproof" on product labels.
- "Water resistant" means the sunscreen is formulated to perform well despite the presence of water or sweat.
- FDA has a specific test and you should find one of two ratings:
  - Water resistant for 40 minutes
  - Water resistant for 80 minutes



UNC HEALTH CARE SYSTEM

---

---

---

---

---

---

---

---

**Sunscreen: SPF**

- SPF 15 blocks 93% of UVB rays
- SPF 30 blocks 97% of UVB rays
- SPF 50 blocks 98% of UVB rays
- SPF 100 blocks 99% of UVB rays



UNC HEALTH CARE SYSTEM

---

---

---

---

---

---

---

---

**Sunscreen: SPF**

- Apply liberally
- 1 oz covers the body

3 oz so  
3 applications



UNC HEALTH CARE SYSTEM

---

---

---

---

---

---

---

---

UNC HEALTH CARE SYSTEM

### Sunscreen: Time between Applications

SPF ratings don't tell you how long you can wait before reapplying.

FDA recommends that you reapply any sunscreen every two hours, regardless of its SPF rating.

swallowed, get medical help or contact a Poison Control Center right away.

**Directions** • apply generously and evenly 15 minutes before sun exposure • reapply: • after 80 minutes of swimming or sweating • immediately after towel drying • at least every 2 hours • Sun Protection Measures: Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including • limit time in the sun, especially from 10 a.m.–2 p.m. • wear long-sleeved

48

---

---

---

---

---

---

---

---

UNC HEALTH CARE SYSTEM

### Sunscreen Regulation Since 2011

UVB and UVA can cause sunburn, skin cancer, and premature skin aging.

Sunscreens labeled broad spectrum to shield skin from both UVB and UVA rays.

In 2011, FDA required sunscreens advertising “broad spectrum” pass a test

FDA says a broad spectrum’s UVA protection level will be roughly proportional to its UVB protection level (SPF rating)

SUNSCREEN

Broad Spectrum SPF 60+

60+

UNC HEALTH CARE 49

---

---

---

---

---

---

---

---

UNC HEALTH CARE SYSTEM

### Sunscreen: Chemical vs Mineral

Active ingredients in sunscreens come in two forms, mineral and chemical filters.

Chemical sunscreens include a combination of two to six of the following active ingredients: oxybenzone, avobenzone, octisalate, octocrylene, homosalate and octinoxate.

Mineral sunscreens use zinc oxide and/or titanium dioxide.

A few products combine zinc oxide with chemical filters.

50

---

---

---

---

---

---

---

---

UNC HEALTH CARE SYSTEM

### Sunscreen Environment Issue

In laboratory experiments, high concentrations oxybenzone caused damage and deformation of coral

Hawaii recently passed a bill, not yet signed into law, to ban sale of oxybenzone-containing sunscreen due to its effects on marine life.

REI vows to ban use of oxybenzone in products sold by fall 2020.

51

---

---

---

---

---

---

---

---

UNC HEALTH CARE SYSTEM

### POLL

Which is an incorrect statement?

- A. Broad spectrum sunscreens protect against UVB and UVA
- B. A waterproof sunscreen lasts indefinitely when you are swimming
- C. SPF 15 sunscreen is the lowest SPF recommended by dermatologists
- D. Sunscreen labels must include warnings about skin cancer

52

---

---

---

---

---

---

---

---

UNC HEALTH CARE SYSTEM

### Towards the control of melanoma

Primary prevention      Secondary prevention      Tertiary prevention

Causal factors      Skin self-awareness and exam      Therapeutic efficacy

Screening

Birth      Onset of melanoma      Diagnosis of melanoma      Death

53

---

---

---

---

---

---

---

---

UNC HEALTH CARE SYSTEM

### Skin Self-Awareness

**Self-Screening for melanoma?**  
***Skin Self-Awareness***  
***Skin Self exam***

Individuals who are more aware of changes in their skin are more likely know be aware of whether or not a mole or other skin mark has changed over time

*Skin Self-Awareness has been show to decrease death from melanoma*

Paddock et al. Melanoma Research 2016, 26:401-408

54

---

---

---

---

---

---

---

---

UNC HEALTH CARE SYSTEM

### Screening for Melanoma

**Screening for melanoma?**  
***Who to screen?***

*Melanoma survivors are screened for second melanomas*  
*No current recommendations for population screening*

55

---

---

---

---

---

---

---

---

UNC HEALTH CARE SYSTEM

### Screening for Melanoma

**Population screening for melanoma?**  
***Targeted Screening?***

Can we *identify* and use *targeted screening* for those at highest risk for melanoma?

- *Increased number of nevi, atypical nevi, fair traits, red hair, increased sun exposure*
- *Genetic?*

56

---

---

---

---

---


---


---


---

UNC HEALTH CARE SYSTEM

### Screening for Melanoma

**Baseline pictures** 

**Dermoscopy**  

**Confocal**  

57

---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

**UNC**  
N.C. CANCER HOSPITAL  
LINDBERGER COMPREHENSIVE  
CANCER CENTER

### Caring for the Patient with Melanoma or Other Skin cancers. Part 2.

Frances Collichio  
Clinical Professor, University of North Carolina, Chapel Hill

Disclosures:  
Amgen  
Novartis/GSK  
Merck

---

---

---

---

---

---

---

---

**At the end of this part of the talk you will:**

- Understand the principles of immuno-oncology
- Apply these principles to the management of a patient with melanoma in lymph nodes.
- Apply these principles to a patient with advanced disease
- Infer what the side effects of the treatments may be and list them

---

---

---

---

---

---

---

---

**Our Case**

A 49 year old married father of two presents on the urging of his wife due to a mole on his right lower leg that seems to have changed. He is in good health and takes no medication. The mole is shown. The rest of the examination is normal.



---

---

---

---


---

---

---

---

**Case 1**



Histologic type:  
Superficial spreading melanoma  
Breslow depth: 1.8 mm  
Ulceration: PRESENT

---

---

---

---

---

---


---

---

## Sentinel Lymph Node Procedure/Clear the margins



Morton N Engl J Med 355 2008




---

---

---

---

---


---

---

---

### Case 1

The sentinel lymph node procedure maps to the right groin. There are three sentinel nodes.




---

---

---

---

---

---

---

---


## Sentinel Lymph Node Evaluation



Lymph node serially sectioned while fresh



Alternate sections paraffin-embedded; remainder snap frozen



Five H&E-stained sections flanked by two S-100 sections

---

---

---

---

---

---

---

---

**AJCC Staging 1/2018**

**T**  
 T0: No evidence of primary tumor  
 Breslow depth  
 Ulceration  
 (Mitoses are no longer part of the staging.  
 T1 category uses 0.8mm as a threshold with T1b of 0.8-1mm w or w/o ulceration)

**N**  
 N0  
 N1 one node is involved  
 N2 two to three  
 N3 4 or more, or matted nodes, or in transit disease, or satellites (tumor w/in 5cm of the primary).  
 Clinically occult or clinically detected (instead of microscopic and macroscopic)  
 "c" categories for microsatellites and in-transit metastases

**M**  
 M1a-skin, subcutaneous tissue or distant lymph nodes  
 M1b-lung  
 M1c-other site  
 M1d-CNS

Stage I, II negative nodes  
 Stage III, positive nodes

**T2bN2aM0 Stage IIIb**

---

---

---

---

---

---

---


---

---

---

**Case 1**

Does the patient need more surgery on his nodes?



One group: No more surgery  
 Other group: Remove the rest of the nodes from the nodal basin

---

---

---

---

---

---


---

---

---

---

Is the patient cured? Can we add to the surgery to increase his chances?




---

---

---

---

---

---

---

---

---

---

Before we go on...you need some immune-oncology concepts

---

---

---


---

---

---

---

### Immune System Overview



---

---

---

---

---

---

---

### Immunotherapy: How the Immune System Fights Cancer

<https://www.youtube.com/watch?v=jDdL2bMQxFE>

or

[uncncn.org/video](http://uncncn.org/video)

This video was created by the National Cancer Institute. Permission was obtained to use this video.

---

---

---

---


---

---

---



Which of the following is the best way to improve this patient's chances?



- A. Complete the surgery on the lymph node basin.
- B. Give six months of chemotherapy
- C. Give a “check point inhibitor”
- D. Nothing, his chances are good.

---

---

---

---

---

---

---

---

Treatments for Melanoma that has gone to the lymph node after surgery

One year of:  
 Anti CTLA 4: Ipilimumab  
 Anti PD1: Nivolumab  
 Anti PD1: Pembrolizumab




---

---

---

---

---

---

---

---

The Next Case:

A 33 year old scientist with a history of surgery for stage II melanoma on her leg presents to the doctor because she is tired. She says she has lost 5 pounds without trying.




---

---

---

---

---

---

---


---

**Our Case 1**

**Her physical examination is normal. Her laboratory tests are normal including white blood cells, red blood cells, liver function and kidney function.**



A biopsy was done of the liver and this was melanoma. A molecular genetic test was done and it showed an abnormal BRAF V600 E gene.



---

---

---

---

---

---

---

---

**What does all this mean?**

What is her stage of cancer?  
Can she be cured?  
What is the gene test?  
How do you know what to treat her with?

---

---

---

---

---

---

---

---

**What is her stage?**

Stage 4  
M1a  
M1b  
M1c  
M1d  
Prognosis is predicted by the patients overall health and the immune markers.

---

---

---

---

---

---

---

---



Choice of therapy

Immune therapy Generally preferred Combination versus single? Combination versus sequence? New Immune agents Biomarkers Caution with existing Autoimmune disease!	Target Therapy Hit the Target: BRAF V600E, 600K Generally works faster than immune therapy Difficult to stop
--	---

---

---

---

---

---

---

---

Answers

What is her stage of cancer?: **Stage 4, M1c**  
Can she be cured? : **Maybe**  
What is the gene test?: **It is a mutation that occurs from the environment. It is not a hereditary mutation**  
How do you know what to treat her with? **This question has taken years of study and we do not have all of the answers but in a young, fit person we start with immune therapy.**

---

---

---

---

---

---

---

Which of the following side effects do you think is common with immune therapy?

- A. Hair Loss
- B. A decrease in red blood cells
- C. Nausea
- D. Rash

---

---

---

---

---

---

---

### Toxicities: Side effects of ipilimumab

Skin




Colon




Liver



Pituitary



Cases of myocarditis have been reported from ipilimumab



---

---

---

---

---

---

---

---

### Toxicities: Side effects of PD1 and PDL1 inhibitors

Hypothyroidism (5%)  
Hyperthyroidism 1%



pneumonitis 3%



Colitis 1%



Hypophysitis 0.5%



Hepatitis 0.5%



Nephritis 0.5%



Other in less than 1%: dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial seizures, adrenal insufficiency.

---

---

---

---

---


---

---

---

### Toxicities: any organ

**IRAE Management: End Organ**



Postow et al. NEJM 2018

Presented By Marc Ernstoff at 2018 ASCO Annual Meeting

---

---

---

---

---

---

---

---

**In conclusion:**

- We covered the principles of immuno-oncology
- We applied these principles to the management of a patient with melanoma in lymph nodes
- We applied these concepts to a patient with melanoma of advanced stage
- We listed the side effects of the treatment.

---

---

---

---

---

---

---